Intravitreal Avastin in Proliferative Retinopathies (SITE-App)

Ophthalmological Association Edelweiss

Status and phase: Completed; Phase 2

Conditions: Retinal Neovascularization

Treatments: Drug: Avastin

Study type: Interventional

Funder types: Other

Identifiers

NCT00564148

AVAST-ro-1

SITE-App

Details and patient eligibility

About

The study intends to assess the effect of Avastin injections in different proliferative retinopathies due to different causes

Full description

Proliferative retinopathies due to different causes represent important causes for the visual acuity loss. Conventional treatments may sometimes improve the visual function, whereas other times, the visual acuity continue to decrease, in spite of all the medical, surgical or laser treatments.

Intravitreal injections with anti-VEGF agents (ex. Avastin for our trial) seem to be an important tool for certain difficult situations in which at the ocular fundus, out of different reasons (advanced age, diabetes mellitus, retinal veins occlusions, etc)new pathologic vessels appear, causing devastating changes in the posterior and anterior segment as well.

Enrollment: 100 estimated patients

Sex: All

Ages: 20+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• clinical diagnosis of a proliferative retinopathy (AGE RELATED MACULAR DEGENERATION,DIABETIC PROLIFERATIVE RETINOPATHY, etc)
• distance acuity < 0.5
• age > 20 years

Exclusion criteria

• noncooperative patients
• ocular infections / inflammations

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

100 participants in 1 patient group

A,1, II

Experimental group

Treatment:

Drug: Avastin